Vilazodone is an antidepressant that also exhibits some anxiolytic efficacy in animal models. Vilazodone inhibits the serotonin transporter (SERT), preventing serotonin reuptake, and also acts as a partial agonist at the 5-HT1A receptor; this compound has negligible activity at other 5-HT receptors or on NETs and DATs. Unlike many other antidepressants, vilazodone does not exhibit any potentially harmful cardiac effects.
| Cas No. | 163521-12-8 |
|---|---|
| Purity | ≥98% |
| Formula | C26H27N5O2 |
| Formula Wt. | 441.52 |
| IUPAC Name | 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide |
| Melting Point | 203-205°C |
| Appearance | Light Tan powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | V3444 Info Sheet PDF |
|---|
Edwards J, Sperry V, Adams MH, et al. Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study. Int J Clin Pharmacol Ther. 2013 Jun;51(6):456-65. PMID: 23611569.
Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005 Mar 7;510(1-2):49-57. PMID: 15740724.
Treit D, Degroot A, kashluba S, et al. Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test. Eur J Pharmacol. 2001 Mar 2;414(2-3):245-8. PMID: 11239925.
